Robeco Institutional Asset Management B.V. Cuts Position in Humana Inc. $HUM

Robeco Institutional Asset Management B.V. lessened its holdings in Humana Inc. (NYSE:HUM) by 54.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 98,411 shares of the insurance provider’s stock after selling 118,759 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Humana were worth $25,206,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HUM. CoreCap Advisors LLC boosted its stake in shares of Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the last quarter. Rosenberg Matthew Hamilton boosted its stake in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares during the last quarter. Mather Group LLC. purchased a new position in shares of Humana in the 3rd quarter worth approximately $34,000. Private Wealth Management Group LLC boosted its stake in shares of Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after buying an additional 48 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Humana by 114.1% in the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after buying an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Sanford C. Bernstein restated an “outperform” rating and issued a $344.00 target price on shares of Humana in a research note on Tuesday, January 6th. Barclays dropped their price objective on Humana from $245.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Raymond James Financial dropped their price objective on Humana from $340.00 to $230.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. JPMorgan Chase & Co. dropped their price objective on Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a research note on Friday, February 13th. Finally, Wolfe Research dropped their price objective on Humana from $325.00 to $250.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Seven investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $224.65.

Insider Activity

In related news, insider Sanjay K. Shetty bought 810 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the transaction, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Humana Price Performance

Humana stock opened at $198.18 on Tuesday. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $315.35. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. The business’s 50 day simple moving average is $180.77 and its 200 day simple moving average is $232.18. The company has a market cap of $23.79 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 2.06 and a beta of 0.44.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating the consensus estimate of ($4.01) by $0.05. The business had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.8%. Humana’s dividend payout ratio is currently 36.05%.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.